Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NICO oral cavity cancer nivolumab study
ISRCTN17428671Phase 2Terminated
- Sponsor
- The Clatterbridge Cancer Centre NHS Foundation Trust
- Start
- Sep 2018
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
01
Overview
Phase 2, open-label trial of nivolumab in Oral Mucosal Carcinoma and mouth cancer (2 cohorts), sponsored by The Clatterbridge Cancer Centre NHS Foundation Trust. Primary endpoints: 1-year disease-free survival in the high-risk population and Feasibility of recruitment. Started Sep 2018; status: terminated.
02
Drugs
03
Conditions
Oral Mucosal Carcinomamouth cancer
Beyond the preview
Go deeper on ISRCTN17428671.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN17428671.